The Financial Express

Biocon Biologics partners Adagio Therapeutics for Covid-19 treatment

Biocon Biologics, a wholly-owned subsidiary of Biocon, has partnered with US-based Adagio Therapeutics for an exclusive licence to manufacture and commercialise an antibody treatment based on ADG20 ...
Mint

Biocon Biologics ties up with Adagio Therapeutics for antibody treatment of Covid-19

Biocon Biologics announced that the US-based Adagio Therapeutics has granted an exclusive license to Biocon Biologics to manufacture and commercialise an antibody treatment based on ADG20 for India ...
Business Wire

Adagio Therapeutics Partners with Biocon Biologics to Bring Potent and Broadly Neutralizing COVID-19 Antibody Treatment to Patients in India and Select Emerging Markets

WALTHAM, Mass.--(BUSINESS WIRE)--Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for ...
health.economictimes.indiatimes

Biocon Biologics partners with Adagio to advance antibody for the management of COVID-19

Bengaluru, India July 26, 2021: Biocon Biologics Ltd., a fully integrated biosimilars company and a subsidiary of Biocon Ltd. announced today that U.S. based Adagio Therapeutics has granted an ...
Mint

Biocon Biologics partners Adagio Therapeutics for antibody treatment of covid

New Delhi: Biocon Biologics Ltd, a subsidiary of Biocon Ltd, has said US-based Adagio Therapeutics has granted an exclusive licence to the company to manufacture and commercialise an antibody ...